Evidence mapPaperPMID 37840653Full record

ReviewFrontiers in nephrology2023

Pathophysiological concepts and screening of cardiovascular disease in dialysis patients.

Gift Echefu, Ifeoluwa Stowe, Semenawit Burka, Indranill Basu-Ray, Damodar Kumbala

Open access · diamondAbstract readReview
In one paragraph

Review in Frontiers in nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Mineralocorticoid Receptor Antagonists in Dialysis.American journal of nephrology · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Gift EchefuDivision of Cardiovascular Medicine, The University of Tennessee Health Science Center, Memphis, TN, United States.
Ifeoluwa StoweDepartment of Internal Medicine, Baton Rouge General Medical Center, Baton Rouge, LA, United States.
Semenawit BurkaDepartment of Internal Medicine, University of Texas Rio Grande Valley, McAllen, TX, United States.
Indranill Basu-RayDepartment of Cardiology, Memphis Veterans Affairs (VA) Medical Center, Memphis, TN, United States.
Damodar KumbalaNephrology Division, Renal Associates of Baton Rouge, Baton Rouge, LA, United States.
Baton Rouge General · USMemphis VA Medical Center · USRenal Associates P. A. · USThe University of Texas Rio Grande Valley · USUniversity of Tennessee Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dialysis patients experience 10-20 times higher cardiovascular mortality than the general population. The high burden of both conventional and nontraditional risk factors attributable to loss of renal function can explain higher rates of cardiovascular disease (CVD) morbidity and death among dialysis patients. As renal function declines, uremic toxins accumulate in the blood and disrupt cell function, causing cardiovascular damage. Hemodialysis patients have many cardiovascular complications, including sudden cardiac death. Peritoneal dialysis puts dialysis patients with end-stage renal disease at increased risk of CVD complications and emergency hospitalization. The current standard of care in this population is based on observational data, which has a high potential for bias due to the paucity of dedicated randomized clinical trials. Furthermore, guidelines lack specific guidelines for these patients, often inferring them from non-dialysis patient trials. A crucial step in the prevention and treatment of CVD would be to gain better knowledge of the influence of these predisposing risk factors. This review highlights the current evidence regarding the influence of advanced chronic disease on the cardiovascular system in patients undergoing renal dialysis.

Indexed as

beta 2-microglobulinchronic kidney diseasegalectin-3hemodialysisleft ventricular hypertrophysuppression of tumorigenicity-2 (ST2)uremic toxins

Identifiers

PMID37840653
PMCPMC10570458
OpenAlexW4387187818

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.